Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) subsidiary Zhangyanming Tablet's clinical trial application has been approved.
Baiyun Mountain (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., has recently received the "Approval Notice for Clinical Trials" issued by the National Medical Products Administration regarding the new functional indications for the Zhangyanming tablets. The Zhangyanming tablets are effective in nourishing the liver and kidneys, dispelling obscure vision, and are used for symptoms such as dryness and discomfort caused by liver and kidney deficiencies, monocular diplopia, weak lower back and knees, or mild vision decline; they are indicated for early and mid-stage senile cataracts exhibiting the aforementioned symptoms. This medication is an already marketed traditional Chinese medicine compound, and this application is for adding clinical trials for the treatment of dry eyes.
Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., has recently received a "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration regarding the new functional indications of Zhangyanming Tablets. Zhangyanming Tablets have the effects of nourishing the liver and kidneys, alleviating eye cloudiness, and clearing the vision. They are used for symptoms caused by liver and kidney deficiency, such as dryness and discomfort in the eyes, monocular double vision, soreness and weakness of the lower back and knees, or mild vision decline; and for early to mid-stage age-related cataracts exhibiting the above symptoms. This drug is an already marketed traditional Chinese medicine compound formulation, and this application is for adding clinical trials for dry eye treatment.
Related Articles
JUNSHI BIO (01877) shareholder He Ming has reduced his holdings by a total of 882,600 shares, and the reduction plan has been completed.
CH GENERAL EDU(02175): Tian Yan has been appointed as Executive Director and a member of the Board Nomination Committee.
MONGOL MINING (00975) canceled 11.748 million shares of repurchased stock on August 10.
JUNSHI BIO (01877) shareholder He Ming has reduced his holdings by a total of 882,600 shares, and the reduction plan has been completed.
CH GENERAL EDU(02175): Tian Yan has been appointed as Executive Director and a member of the Board Nomination Committee.
MONGOL MINING (00975) canceled 11.748 million shares of repurchased stock on August 10.
RECOMMEND
